CO7061067A2 - Métodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas - Google Patents

Métodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas

Info

Publication number
CO7061067A2
CO7061067A2 CO14072652A CO14072652A CO7061067A2 CO 7061067 A2 CO7061067 A2 CO 7061067A2 CO 14072652 A CO14072652 A CO 14072652A CO 14072652 A CO14072652 A CO 14072652A CO 7061067 A2 CO7061067 A2 CO 7061067A2
Authority
CO
Colombia
Prior art keywords
aminopyridines
sensory
stroke
treatment
methods
Prior art date
Application number
CO14072652A
Other languages
English (en)
Inventor
Blight Andrew R
Caggiano Anthony O
Parry Tom J
Iaci Jennifer F
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of CO7061067A2 publication Critical patent/CO7061067A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CO14072652A 2011-10-04 2014-04-04 Métodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas CO7061067A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161543150P 2011-10-04 2011-10-04
US201261591833P 2012-01-27 2012-01-27
US201261648695P 2012-05-18 2012-05-18

Publications (1)

Publication Number Publication Date
CO7061067A2 true CO7061067A2 (es) 2014-09-19

Family

ID=47143280

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14072652A CO7061067A2 (es) 2011-10-04 2014-04-04 Métodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas

Country Status (21)

Country Link
US (2) US20130085167A1 (es)
EP (1) EP2766017B1 (es)
JP (1) JP6134722B2 (es)
KR (1) KR20140084120A (es)
CN (2) CN104220072B (es)
AR (1) AR088764A1 (es)
AU (2) AU2012318719B2 (es)
BR (1) BR112014008082A8 (es)
CA (1) CA2850635A1 (es)
CL (1) CL2014000799A1 (es)
CO (1) CO7061067A2 (es)
CR (1) CR20140153A (es)
EA (1) EA029558B1 (es)
HK (2) HK1201204A1 (es)
IL (1) IL231809B (es)
MX (1) MX354667B (es)
SG (2) SG11201401248YA (es)
TW (1) TWI592156B (es)
UA (1) UA114486C2 (es)
WO (1) WO2013052575A1 (es)
ZA (1) ZA201402432B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014172266A1 (en) * 2013-04-15 2014-10-23 Acorda Therapeutics, Inc. Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines
CN106511293B (zh) * 2015-09-11 2020-08-04 法德生技药品股份有限公司 含有达方吡啶的缓释口服制剂及其用途
DE102017115701B4 (de) * 2017-07-12 2022-03-03 Lts Lohmann Therapie-Systeme Ag Fampridin-TTS
CN109172573B (zh) * 2018-09-12 2021-01-26 黑龙江中桂制药有限公司 一种口服抗血栓药物及其用途
CN115018836A (zh) * 2022-08-08 2022-09-06 四川大学 一种癫痫病灶自动分割与预测方法、系统及设备

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0696575B2 (ja) * 1987-09-17 1994-11-30 三菱化成株式会社 ４−アミノピリジン誘導体及びその酸付加塩
JPH03505868A (ja) * 1988-04-08 1991-12-19 マサチユセツツ・インスチチユート・オブ・テクノロジー 神経性疾患を治療するための方法及び組成物
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
CA2085785C (en) * 1992-12-18 2005-03-15 Robert R. Hansebout The use of 4-aminopyridine in the treatment of a neurological condition
US5952357A (en) 1993-12-23 1999-09-14 Cornell Research Foundation, Inc. Treating diseases of the anterior horn cells
AU3360000A (en) * 1999-02-09 2000-08-29 Uab Research Foundation Use of 4-amino pyridine for treatment of peripheral neuropathies
FR2791571B1 (fr) * 1999-04-02 2002-10-04 Sod Conseils Rech Applic Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s)
AU2001242184A1 (en) * 2000-03-28 2001-10-08 Queen:S University At Kingston Methods for effecting neuroprotection using a potassium channel modulator
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
US20100095132A1 (en) * 2007-01-26 2010-04-15 Safenet, Inc. Protecting secrets in an untrusted recipient
BR112013019265A2 (pt) * 2011-01-28 2016-10-11 Acorda Therapeutics Inc uso de bloqueadores do canal de potássio no tratamento da paralisia cerebral

Also Published As

Publication number Publication date
CN108451953A (zh) 2018-08-28
WO2013052575A1 (en) 2013-04-11
TWI592156B (zh) 2017-07-21
AR088764A1 (es) 2014-07-02
ZA201402432B (en) 2020-08-26
KR20140084120A (ko) 2014-07-04
NZ623255A (en) 2016-08-26
CN104220072A (zh) 2014-12-17
AU2012318719A1 (en) 2014-04-17
BR112014008082A8 (pt) 2018-01-16
MX2014003997A (es) 2014-07-22
US20160067232A1 (en) 2016-03-10
JP6134722B2 (ja) 2017-05-24
US20130085167A1 (en) 2013-04-04
TW201321000A (zh) 2013-06-01
CR20140153A (es) 2014-07-04
UA114486C2 (uk) 2017-06-26
CA2850635A1 (en) 2013-04-11
SG11201401248YA (en) 2014-05-29
EP2766017A1 (en) 2014-08-20
MX354667B (es) 2018-03-15
AU2012318719B2 (en) 2017-10-19
IL231809A0 (en) 2014-05-28
HK1204965A1 (en) 2015-12-11
CN104220072B (zh) 2018-04-17
BR112014008082A2 (pt) 2017-07-18
CL2014000799A1 (es) 2014-11-03
EA201490562A1 (ru) 2014-08-29
EP2766017B1 (en) 2020-07-01
IL231809B (en) 2019-06-30
SG10201600410SA (en) 2016-02-26
EA029558B1 (ru) 2018-04-30
JP2014531470A (ja) 2014-11-27
AU2018200114A1 (en) 2018-01-25
HK1201204A1 (en) 2015-08-28

Similar Documents

Publication Publication Date Title
CR20140034A (es) Métodos para tratar el cáncer por el uso de antagonistas de unión al eje pd-1e inhibidores de mek
CL2014001795A1 (es) Dispositivo de carbonatacion y metodo de carbonatacion mediante el uso de dicho dispositivo
CO6821893A2 (es) Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b
BR112015027657A2 (pt) Aparelho para uso com ferramentas eletromecânicas
BR112015016579A2 (pt) métodos de pesquisa de aquisição sísmica por disparos nodais simultâneos
CO6791602A2 (es) Métodos y sistemas para el tratamiento de pozos
CO6821964A2 (es) Compuestos para el tratamiento de la adicción
BR112015002091A2 (pt) método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição
SMT201500057B (it) Uso della biotina per il trattamento della sclerosi multipla
CO6920293A2 (es) Compuestos antibaterianos y método para su uso
BR112013034055A2 (pt) alcaftadina para uso no tratamento de urticária
DK2505748T3 (da) Låsecylinder
CO7061067A2 (es) Métodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas
DK2807170T3 (da) Phragmalin-limonoider til behandlingen af seksuel dysfunktion
BR112013030248A2 (pt) aeronave
BR112013027627A2 (pt) processo contínuo para produzir um perfil, perfil, uso de um perfil, e, aparelho para realizar o processo
CL2014003400A1 (es) Espuma de cemento autoendurecible; cañon de espuma; dispositivo para la fabricacion de dicha espuma; y procedimiento para la fabricacion de dicha espuma.
BR112013023039A2 (pt) dispositivos de trava para uso com atuadores rotativos
BR112013033892A2 (pt) método para produzir um elastômero com enchedor, elastômero com enchedor, e, uso de um elastômero com enchedor
CL2014002480A1 (es) Método para reducir el uso de antiespumante de silicona en procesos de coquizacion retardada
CO6880061A2 (es) Método para tratar el cáncer mediante el uso combinado de fármacos
CR20130362A (es) Método para el control de hongos fitopatógenos
BR112013022474A2 (pt) aparelho de derivação para tanque de absorção
ES1073946Y (es) Dispositivo para el pesaje de personas
BR112014000239A2 (pt) revestimento de superfície

Legal Events

Date Code Title Description
FA Application withdrawn